Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Daiichi Sankyo Inks Deal For Lilly’s Evista

This article was originally published in PharmAsia News

Executive Summary

Munich, Germany-based Daiichi Sankyo Europe GmbH announced that its Japanese parent Daiichi Sankyo Group has purchased European rights to the osteoporosis medication Evista (raloxifene)from Lilly. Daiichi plans to expand marketing of Evista from eight European countries to 34. The Japanese company predicts growth in sales from €20 million currently to approximately €80 million. (Click here for more - Japanese language

Related Content

Daiichi Sankyo To Expand European Presence With Acquisition Of 130 Merck KGaA Medical Reps



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts